about
Familial focal segmental glomerulosclerosis (FSGS)-linked α-actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptorsα-Actinin 4 potentiates nuclear factor κ-light-chain-enhancer of activated B-cell (NF-κB) activity in podocytes independent of its cytoplasmic actin binding functionNonimmunologic targets of immunosuppressive agents in podocytesInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An UpdateUnderstanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsComparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort studyDose- and time-dependent glucocorticoid receptor signaling in podocytes.Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte productInduction of podocyte VEGF164 overexpression at different stages of development causes congenital nephrosis or steroid-resistant nephrotic syndromeSignificance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trialPathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin.Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection.Microarray analyses of glucocorticoid and vitamin D3 target genes in differentiating cultured human podocytesAdvances in the biology and genetics of the podocytopathies: implications for diagnosis and therapyMinimal change disease as a modifiable podocyte paracrine disorder.Nephrotic syndrome in children: from bench to treatmentComparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects.Marker expression, behaviors, and responses vary in different lines of conditionally immortalized cultured podocytes.Dexamethasone-dependent modulation of cyclic GMP synthesis in podocytes.A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules.Current concepts of the podocyte in nephrotic syndrome.Nuclear hormone receptors in podocytesThe role of osteopontin in the development of albuminuria.Albuminuria is associated with too few glomeruli and too much testosteronePodocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGSAdrenocorticotropic hormone analog use for podocytopathiesThe podocyte as a direct target for treatment of glomerular disease?Urinary IgG and α2-macroglobulin are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide in idiopathic focal segmental glomerulosclerosis with nephrotic syndromeRituximab in idiopathic nephrotic syndrome: does it make sense?Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids.Recent advances in understanding and treating nephrotic syndrome.Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytesPathogenesis and therapy of focal segmental glomerulosclerosis: an update.Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.The podocyte as a target for therapies--new and old.Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.Podocyte dedifferentiation: a specialized process for a specialized cell.The importance of podocyte adhesion for a healthy glomerulus.Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target.Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes.
P2860
Q24305523-C10C94D5-F3D3-4B63-A715-22853E78D850Q24306841-AB7EFB7B-9100-406E-AD33-113DF72914F7Q26781358-FA8E7B71-2486-4C4B-A8B0-497C2A0BE1E3Q33586501-A0BA4BD7-A6A9-4860-A249-80D6CFB06804Q33698419-B0E2B213-07E9-41E3-B94E-602BC33ABA46Q33715862-D0E7FDF4-C610-40A6-8717-13E1247EE2E2Q34211595-534511AA-C626-4FB4-BB77-062444C8D2E6Q34211611-D421A7BA-7CAE-469F-B7A9-73D18541792EQ34254364-BB110222-7F74-445F-A7F7-83FC254398EFQ34324240-FF3F6629-3D10-4BD7-B7DF-CF637337ADBEQ34478786-195FB744-E577-4235-BCB6-82B62ADD198BQ34534855-0CFE9069-A16F-4ABF-A1E2-A93A7F21CC15Q34672764-BD4E4694-5CAC-41B1-966C-BD765C566250Q35056271-F932DFD3-0D8F-4B54-BBA0-68602D46B7D8Q35133160-D2F28F41-22C3-43F1-A3EB-6BC0D58FA601Q35185376-965BB77E-7BF9-4AB0-92D4-DD7D2D33D1AAQ35188070-599B14A6-B1CB-4DF7-9E26-C662C2DF5CD9Q35216791-6C9CA6F6-B4E9-46C3-85FB-301340C681C7Q36109237-5202BE44-FEDF-453B-A56E-906F1028A1CAQ36223325-CB8BA896-1464-4E9C-95B6-1B041DACECA0Q36468648-63E04F68-4471-41C7-B4AE-5F12F2A65CDCQ36527306-8C8E9F7C-00AF-4B73-9C74-EEACE03A025DQ36662121-24135E31-42AA-4BE5-AE3D-6AF84705A8B8Q36907202-62FB305E-3FD6-4A85-983C-5F1B56C3FEADQ36923664-9E8AD2C7-5109-453E-ABA7-D56114CD149BQ37070458-BB6266AD-09C5-466A-BD19-BF9396E8C9BBQ37139449-F0704AAB-00A5-4149-9D1B-5C4378A1A90BQ37182778-F9AE9B86-9540-4D94-ACD0-B9F0136C5380Q37375752-CAB9BB69-FFC0-4E64-94B3-31B633738148Q37411622-6F828DB1-B111-4D5C-AAB9-9B758DCB6A00Q37635783-ABCD66FA-DA1F-4176-B95D-D60E23319E0DQ37714138-3E3E66E9-7CB2-45BC-A5A7-5D1D4FF3AF4AQ37812564-8A01E242-9FBE-45F9-8A96-04C647072A8BQ37904098-A367A092-2D6D-42D6-ACD4-C5BD14B36BE0Q37951800-82A75535-D4C7-4562-A3C7-7BDB7C8E96C3Q38072297-C268BC2E-4BAB-4D5B-97CC-3E93AD72D1ECQ38261014-FFA27CC2-06F3-46E7-A27D-23752DBA515EQ38263509-5204F739-210A-494A-A3C3-FC86DBFD35CCQ38269878-F7C94F33-5531-4C08-82FF-0A02E8B7EEABQ38395906-874DE59C-5DA2-464D-A1F9-840524B54CCB
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Direct effects of dexamethasone on human podocytes.
@en
type
label
Direct effects of dexamethasone on human podocytes.
@en
prefLabel
Direct effects of dexamethasone on human podocytes.
@en
P2093
P356
P1433
P1476
Direct effects of dexamethasone on human podocytes.
@en
P2093
P2888
P304
P356
10.1038/SJ.KI.5001655
P407
P577
2006-07-12T00:00:00Z